Umbilical cord blood (UCB) is a readily available source of hematopoietic stem cells for transplantation. UCB hematopoietic SCT for average-and large-sized patients is often limited by the number of cells available in a single unit. To address this limitation, we performed experiments to determine if adjunctive therapy with third-party human allogeneic cells enhances the engraftment of human UCB in immunodeficient mice. UCB cells with or without sequential infusion of irradiated third-party allogeneic cells were used in transplantation studies of NOD/SCID and NOD/SCID-IL2Rg null mice. We studied the impact of irradiated allogeneic cells on colony formation in vitro using long-term culture assays also. Our studies demonstrate that short-and long-term UCB engraftment of immunodeficient mice is enhanced by irradiated allogeneic cells. Secondary transplants demonstrate the durability of engraftment. These preclinical studies support the further development of irradiated allogeneic cells as an adjunct to single UCB transplantation when limiting numbers of cells are available.
INTRODUCTION
Hematopoietic SCT (HSCT) is a widely used therapy that can provide curative treatment for patients with hematopoietic malignancies, BM failure, specific metabolic disorders, hemoglobinopathies and immunological disorders. Standard hematopoietic stem cell (HSC) donor sources include BM or cytokinemobilized blood from HLA-matched related or unrelated donors. Approximately 20-30% of patients who might benefit from HSCT have a matched related donor, and of the rest B50% do not have an available HLA-matched unrelated donor. Within the population lacking a related donor, there is a racial and ethnic disparity in the availability of HLA-matched unrelated donors. Some of this disparity may relate to representation of the racial or ethnic minority in the donor pool, however, a major component of the disparity relates to the greater HLA genetic diversity of patients of certain racial or ethnic groups. [1] [2] [3] [4] [5] [6] [7] [8] For patients without a matched related or unrelated donor, umbilical cord blood (UCB) is an alternate source for transplantation. 1, 9, 10 Advantages to UCB include the rapid availability of banked cells and the lower stringency of donor-recipient HLA-matching required. Therefore, banked UCB is an excellent donor source for individuals who might benefit from HSCT but who do not have a donor. The lower HLA stringency requirements allows identification of a donor for many patients with rare HLA haplotypes. 6 For example, in one analysis of UCB transplantation from Memorial Sloan-Kettering Cancer Center, nearly 50% of UCB recipients were of African, Hispanic, Asian or Middle-Eastern descent. 1 However, despite the broad genetic applicability that makes even people with rare HLA types eligible, a major barrier to widespread use of UCB transplantation is the small size of many UCB units. This is a critical issue because small units (o2.5 Â 10 7 nucleated cells/kg recipient weight) do not reliably support engraftment.
Some approaches used to enhance UCB engraftment include: (i) UCB expansion ex vivo; [11] [12] [13] (ii) cotransplantation of a single-unit UCB with highly purified haploidentical CD34 þ cells to provide early engraftment; 14 and (iii) the use of two UCB units to overcome low cell numbers. 1, 9, 15, 16 Each of these strategies has some important drawbacks. UCB expansion has been attempted using various culture techniques, but evidence of clinical benefit using 'expanded' UCB has not been consistently demonstrated yet. 17, 18 Notch-mediated ex vivo expansion of CD34 þ cells from one UCB unit as part of a double UCB transplant has been tested in human transplantation with improvement in early myeloid recovery derived from the expanded cells, but limited contribution of the expanded cells to long-term engraftment.
if the lesser HLA-matched unit predominates. The use of two units also makes it more difficult to refine donor selection by ABO type, KIR ligand match, or other graft parameters. [18] [19] [20] [21] [22] There are several other modalities being developed to facilitate engraftment of UCB units with limiting numbers of cells. Mesenchymal stem cells have been studied as an adjunct to UCB transplantation with the objective of enhancing engraftment. 18, 23, 24 Intra-marrow injection of UCB cells has also been studied. 18, 25, 26 Both of these approaches show promise and are being further developed. 25, 27 In this manuscript we describe our preclinical experiments using irradiated allogeneic PBMCs to facilitate UCB engraftment. The rationale for our studies is based on studies by others demonstrating T-cell enhancement of engraftment in human allogeneic HSCT. T-cell depletion to diminish GVHD results in increased rates of graft failure [28] [29] [30] [31] [32] and even third-party T cells may facilitate BM engraftment in some settings. 33 34, 35 In the setting of these studies, we tested irradiated third-party PBMCs as an adjunctive therapy to enhance engraftment of UCB after transplantation in immunodeficient mice. We studied irradiated PBMCs because donor-derived T cells and other adjunctive cells support HSCT engraftment in other settings, even when irradiated. [33] [34] [35] These studies are important because third-party-irradiated allogeneic PBMCs are a readily available cellular agent already safely administered to patients in phase 2 clinical trials. 36, 37 They are easy to obtain and process, are well-tolerated and inexpensive. Successful utilization of irradiated allogeneic cells as an adjunct to enhance UCB engraftment may broaden the applicability of single UCB unit transplantation greatly, allowing potentially curative therapy to be administered to patients currently excluded from such therapy.
MATERIALS AND METHODS

UCB samples
UCB samples were provided by the The New Jersey Cord Blood Bank Umbilical Cord Blood Program (Allendale, NJ, USA and Camden, NJ, USA) through an IRB-approved protocol. Leukocyte-depleted frozen UCB MNCs were used for both in vitro and in vivo experiments. Leukocyte-depleted fresh UCB samples were frozen in aliquots both as unmanipulated MNCs and after CD34 þ cell selection. All samples were thawed and washed with 1:1 (v:v) mixture of Dextran 40 in 0.9% NaCl (Baxter Healthcare, Deerfield, IL, USA) and 5% Human Serum Albumin (Baxter Healthcare) in PBS.
PBMCs
Approximately 40 mL of human blood were collected by phlebotomy from healthy volunteers. After density gradient centrifugation on Histopaque (Sigma-Aldrich, St. Louis, MO, USA), interphase cells were collected and washed several times. Approximately 7 Â 10 7 PBMCs were collected from each volunteer. PBMCs used for the long-term culture assay and mixed lymphocyte cultures were labeled with 20 mM 5(6)-carboxfluorescein diacetate N-succinimidyl ester (BioChemika/Sigma-Aldrich, St. Louis, MO, USA) according to manufacturer's protocol. Cells were irradiated with 2500 cGy, as indicated.
UCB samples (n ¼ 5 samples) and peripheral blood samples (n ¼ 3 samples) were mismatched at low-resolution HLA typing.
Mice
Human UCB transplants were performed in NOD/SCID (NOD/Ltsz-Prkdc (SCID/J)) and NOG (NOD/SCID-IL2R g-null) mice purchased from Jackson Labs (Bar Harbor, ME, USA). The first set of experiments was performed using NOD/SCID mice, however, poor peripheral marking in this strain prompted us to change the mouse strain to the NOG mouse strain. The NOG transplant model offered better peripheral human hematopoiesis with relatively lower number of UCB MNCs. The mice used for engraftment studies were 6-8-week-old females. Animals were housed in a barrier facility under stringent pathogen-free conditions in filter-top cages. The mice were handled in sterile cross flow hoods and given access to ad-lib sterile food and water. 
Flow cytometry
Samples were immunostained with fluorochrome-labeled anti-human monoclonal antibodies: anti-human CD45-APC (BD Pharmingen, San Jose, CA, USA), anti-CD3-FITC anti-CD4-APC, anti-CD14-TC, anti-CD20-PE, antihuman CD45-FITC, anti-CD38-APC and anti-CD34-PE (Invitrogen, Carlsbad, CA, USA) and anti-mouse CD45.1-PE Ab (BD Pharmingen). Three weeks after transplant, BM was harvested from NOD/SCID mice and human engraftment evaluated with immunostaining. The NOG mice were bled bi-monthly from the cheek vein and their blood samples were immunophenotyped for evaluating human hematopoiesis. Human hematopoiesis was evaluated with three different immunostaining protocols: (i) anti-human-CD45-APC and anti-mouse-CD45-PE; (ii) anti-human CD45-APC, anti-CD3-FITC and anti-CD15-PE; and (iii) anti-CD45-FITC, anti-CD20-PE and anti-CD14-TC. The first group of samples was stained with antibodies, then the cells were washed and resuspended in PBS with FBS, and 7-aminoactinomycin was added. After 10 min of incubation at room temperature, up to 50 000 cells were analyzed on a FACS Calibur (BectonDickinson, San Jose, CA, USA) using Cellquest software (Becton Dickinson, Franklin Lakes, NJ, USA). Sequential gates were set to include viable cells (R1 gate from FSC vs SSC, R2 gate from SSC and 7-aminoactinomycin staining), and quadrant markers were set to exclude at least 99.9% of cells labeled with relevant isotype controls. For determining the origin of the erythroid cells, samples were stained both with Ter199-PE (specific for mouse erythroid lineage) and Glycophorin A-FITC (specific for human erythroid lineage), and samples were analyzed without erythrocyte lysis.
Colony-forming unit assay
Colony assays testing for HSC were performed using Human Methocult methylcellulose media (StemCell Technologies #04434, Vancouver, Canada). Non-irradiated PBMCs, irradiated PBMCs and UCB MNCs were plated at a concentration of 5 Â 10 4 cells/mL (1 mL/35 mm dish; in duplicates) and incubated at 371C for 14 days. Colony counts for burstforming unit erythrocyte, colony-forming unit granulocyte and macrophage, and colony-forming unit granulocyte-eryhtrocyte-macrophagemegakaryocyte were assessed.
Multiplex cytokine, chemokine, and growth factor assay Either 10 3 CD34 þ cells or 10 4 UCB MNCs were plated on the Hs27a stromal cells (ATCC CRL-1634) with or without 1 Â 10 6 irradiated or unirradiated PBMCs in T12.5 flasks. Daily, 400-ul supernatant was collected, spun at 3000 g for removing cellular components, and frozen in 100-ml aliquots for multiplex assays. The experiment was designed for three different UCB-derived MNCs, and their derived CD34 þ cells. Culture supernatants were collected for 5 days. Monoclonal antibodies against human IL-2, IL-3, IL-4, IL-6, IL-10, IL-17, INF gamma (IFN-g), TNF-a, SCF, stem cell-derived factor-1 alpha (SDF-1a), M-CSF, and their relevant human cytokine standards were purchased from Bio-Rad Laboratories (Hercules, CA, USA). Culture supernatants were assayed for the cytokines, chemokine and growth factors listed above with a multiplex bead array kit (Bio-Plex Pro, Bio-Rad Laboratories, Hercules,CA, USA) using Luminex Technology (Bi-Pelx, Bio-Rad) according to the manufacturer's protocol.
Cell separation CD34 þ cells were isolated using MACS magnetic column separation system (Miltenyi Biotec, Auburn, CA, USA). Cells were magnetically labeled with CD34 þ magnetic MicroBeads and then run through magnetic columns according to manufacturer's specifications. The positive cell fraction was run through a second column to increase purity. Cell viability and cell purity were assessed by flow cytometry.
Long-term culture-initiating cell assays Hs27a stromal cells 38 were grown using Dulbecco's Modified Eagle's Media (DMEM; Gibco, Carlsbad, CA, USA), 10% FBS (Gemini, West Sacramento, CA, USA) and 1% Penicillin/Streptomycin (Gibco). On the day before initiating long-term cultures, T12.5cm 2 flasks and flat bottom 96-well plates were plated with Hs27 stromal cells at a concentration of 6 Â 10 4 cells/cm 2 , using Iscove's Modified Dulbecco's Media (Gibco) with 12.5% FBS, 12.5% Horse Serum (Gemini), 10 À 6 M Hydrocortisone (StemCell Technologies) and 1% Penicillin/Streptomycin. The plates and flasks containing stromal cells were then irradiated at 2000 cGy. On the following day, UCB MNCs (unfractionated) or CD34 þ cells fractionated from UCB samples were layered on top of the stromal cells with or without 1 Â 10 6 irradiated or non-irradiated third-party PBMCs (Supplemental Figure 1) 
frequencies between groups during an 18-week follow-up.
RESULTS
Irradiated allogeneic cells facilitate UCB engraftment in NOD/SCID mice The experiments described in this manuscript were designed to determine if irradiated allogeneic cells, a readily available product already utilized in clinical trials, 36, 37 should be developed as an adjunctive cellular therapy to support UCB transplantation when there are limiting numbers of UCB cells available for transplant. Therefore, in our initial experiments we transplanted UCB MNCs with or without sequential infusion of irradiated third-party human PBMCs into sublethally irradiated (350 cGy) NOD-SCID mice. The UCB sample contained 0.84% CD34 þ cells, while thirdparty PBMCs had only 0.08% CD34 þ cells. Irradiated PBMCs neither formed hematopoietic colonies in vitro nor exhibited in vivo engraftment (Figure 1a) . Human hematopoietic engraftment levels in BM samples were determined by human CD45 (hCD45) Ab staining. Mice were considered engrafted if flow cytometry of BM cells demonstrated 40.5% hCD45 þ cells with evidence of myeloid (CD15 þ ), T lymphoid (CD3 þ ), B lymphoid (CD19 þ ) and human erythroid (Glycophorin A) cells (Figure 1 ). Data from a representative mouse transplanted with both UCB MNCs and irradiated PB MCs show the multilineage engraftment 3 weeks after transplant (Figures 1b-h ).
Animals were injected with unfractionated UCB samples containing 5040 (n ¼ 10), or 2520 (n ¼ 12) CD34 þ cells with or without infusion of 10 6 irradiated (2500 cGy) third-party PBMCs, and three animals received only irradiated PBMCs as the control group. Three weeks after transplant, BM samples revealed significantly higher hCD45-positive cells in the animal groups that received both UCB MNCs and irradiated PBMCs (Po0.03) (Figure 1i) . These initial data demonstrate that short-term engraftment of UCB in NOD-SCID mice is greatly enhanced by sequential infusion of irradiated third-party PBMCs. Similar experiments in NOD/SCID-IL2Rgnull (NOG) mice indicated enhanced engraftment after 3 and 18 weeks when UCB MNC transplantation was followed by infusion of irradiated third-party PBMCs (Figure 1j) .
Longitudinal engraftment profiles of these two transplant modalities were further compared in NOG mice. After sublethal irradiation (240 cGy), female mice were transplanted with UCB MNCs. Animals were injected with unfractionated UCB cells containing 8 Â SRC frequency (1 in 7019 vs 3967 CD34( þ ) cells, Po0.05) in the animal groups that were transplanted with both UCB MNCs and irradiated PBMCs (Figure 2a) . During 18-week follow-up, there was a change in SRC frequency as well as engraftment levels of each individual animal (Figures 2a and c-n) , but animals transplanted with both UCB MNCs and third-party-irradiated PBMCs had significantly higher overall SRC frequency than the animals transplanted with UCB MNCs only (Po0.01).
Secondary transplants demonstrate long-term engraftment potential of UCB cotransplanted with irradiated allogeneic cells To establish the durability of engraftment, secondary transplants were performed. The donors were animals previously transplanted with UCB MNC þ / À irradiated third-party PBMCs. Irradiated PBMCs were not used to support any of the secondary transplants. Primary transplant animals were killed after 18 weeks of posttransplant follow-up, and BM cells were harvested and transplanted into sublethally irradiated secondary transplant recipients. Engraftment levels were higher in mice that received transplants from animals that had received irradiated PBMCs as an adjunct to their primary UCB transplant. The level of human hematopoiesis in secondary transplants from primary recipients that received the highest dose of UCB MNCs alone had a lower level of engraftment than the animals transplanted from primary recipients that received a similar dose of UCB MNCs þ irradiated third-party PBMCs (Figure 3a) . This difference was evident at both 4 and 15 weeks after secondary transplant. The level of hCD45 þ Increased cord blood engraftment with adjuvant cells T Budak-Alpdogan et al expression in the secondary transplant group receiving transplant from mice that had been transplanted previously with UCBcontaining 8000 CD34 þ cells was comparable to the level of engraftment in secondary transplant recipients that had received previously UCB-containing 888 CD34 þ cells þ infusion of irradiated PBMCs (Figure 3a) . All secondary transplant recipients with human hematopoiesis had multilineage engraftment (Figures 3b-g ).
Irradiated allogeneic cells stimulate ex vivo UCB hematopoietic colony formation The above studies demonstrate that irradiated allogeneic cells facilitate UCB hematopoietic engraftment in immunodeficient mice and that the engraftment is durable. To initiate mechanistic studies, we undertook experiments to determine if irradiated third-party allogeneic cells enhance human UCB hematopoiesis ex vivo. We utilized an ex vivo model for human UCB HSC engraftment using the human BM-derived stromal cell line Hs27a as a feeder layer 38, 39 (Supplemental Figure 1) . This cell line supports the development of cobblestone areas from early HSCs. 38 To determine if irradiated third-party PBMCs affect ex vivo UCB hematopoietic colony formation, UCB MNCs or purified UCB CD34 þ cells were plated on irradiated confluent Hs27a cells with or without irradiated PBMCs (Supplemental Figure 1 ). CD34 þ selection depleted most of the T and B cells that were contained in the UCB MNC samples (Supplemental Figure 1b and e). PBMCs contained approximately 2 log less CD34 þ cells, and after irradiation did not form progenitor colonies in semi-solid MethoCult media. To determine cobblestone colonies, plates were demipopulated twice weekly and phase contrast-positive colonies containing at least 15 cells were scored as a cobblestone area at the end of 5 weeks. Wells containing at least one cobblestone area were labeled as positive wells, and the ratio of negative wells to total number of wells were calculated for defining LTC-IC frequency with Poisson distribution. The mean LTC-IC frequencies for UCB CD34 þ cells and UCB MNCs were 1/155 CD34 þ cells and 1/12 531 UCB MNCs (Figure 4) . Coculturing with third-partyirradiated PBMCs increased the frequencies to 1/58 CD34 þ cells and 1/5688 UCB MNCs. However, using unirradiated PBMCs in the coculture decreased the LTC-IC frequencies approximately threefold to 1/435 CD34 þ cells and 1/45 310 MNCs, respectively (Figure 4b ). These changes in LTC-IC frequencies were statistically significant (Po0.03). Increased granulation and detachment of Hs27a cells were noted in wells with unirradiated PBMCs.
Multiplex chemokine, cytokine and growth factor assays Recent studies of double UCB transplantation demonstrate enhanced engraftment with the combined use of units that individually have too few cells for single UCB transplantation. 1, 9, 20, 40 In those studies a single unit ultimately dominates hematopoiesis in most patients. An immune reaction between the donor units has been demonstrated, with the engrafting unit having immune reactivity against the non-engrafting unit. 41 This scenario raises the possibility that the immune reactivity between the two units creates a cytokine milieu that fosters engraftment. Therefore, we tested our cocultures of UCB cells and PBMCs (irradiated and unirradiated) to determine if a unique pattern of cytokine release could be detected. Multiple cytokines, chemokines and growth factors (IL-2, IL-3, IL-4, IL-6, IL-10, IL-17, IFN-g, TNF-a, SCF, SDF-1a, M-CSF) were assayed in culture supernatants. Irradiated PBMCs were not altering the cytokine/ chemokine profiles tested in a consistent manner at multiple time points. Hence, the observed effects of irradiated PBMCs on ex vivo LTC-IC could not be demonstrated in our studies to be a function of an alteration of the amounts of any of the cytokines or chemokines we tested.
DISCUSSION
UCB is an excellent source of HSCs for patients lacking a fully HLA-matched related or unrelated donor for HSCT. To address the barrier to UCB transplantation imposed by the limiting number of cells in many single UCB units, we performed preclinical studies of irradiated allogeneic cells as an adjunctive therapy designed to enhance engraftment. Our research group has developed irradiated haploidentical allogeneic cells for clinical use as an anti-neoplastic agent previously. 36, 37 Irradiated allogeneic cells are readily available, easy to obtain, require minimal processing, are well-tolerated and are inexpensive. The studies presented in this manuscript demonstrate that infusion of irradiated allogeneic cells after administration of UCB MNCs enhances short-term and longterm in vivo engraftment in immunocompromised mice. The benefit was seen in primary and secondary transplants. These results support the use of third-party-irradiated allogeneic cells in clinical trials designed to develop new methods to enhance the engraftment of single UCB units. Columns represent mean ± s.e.m. of three independent experiments. Coculturing of irradiated PBMCs with either (a) purified UCB CD34 þ cells or (b) UCB MNCs increased the LTC-IC frequencies. The mean LTC-IC frequencies of three experimental conditions from three independent experiments compared using Kruskal-Wallis non-parametric test and Dunn's Multiple Comparison. In LTC assays, UCB MNCs formed cobblestone areas more frequently when plated with irradiated PB MCs, and the mean frequencies for both CD34( þ ) cells and UCB MNCs were more than the frequencies obtained by plating the cells either alone or with unirradiated PB MCs (Po0.05 for all comparisons).
To initiate mechanistic studies, experiments were undertaken to determine if there was direct stimulation of hematopoiesis by irradiated third-party PBMCs. In those studies, irradiated thirdparty allogeneic cells enhanced ex vivo UCB LTC-IC hematopoietic colony formation. However, we could not detect a cytokine difference that was specific to cultures containing irradiated PBMCs when measuring IL-2, IL-3, IL-4, IL-6, IL-10, IL-17, IFN-g, TNF-a, SCF, SDF-1a or M-CSF levels. Other explanations for enhanced colony formation, such as other soluble factors, or cell-to-cell interactions between different cell subsets, including mixed lymphocyte reactions, will need to be addressed in future studies.
The hypothesis that irradiated third-party PBMCs enhance UCB engraftment was based upon the work of others demonstrating that T cells (and other cells) facilitate HSC engraftment after allogeneic transplant. Our results indicate that this enhancement extends to the use of irradiated human third-party PBMCs administered after UCB transplantation in immunodeficient mice. Irradiated cells have been used as a transplant adjuvant in laboratory studies 35 but the cells utilized have been of donor origin, a situation not readily applicable to UCB transplantation. The impact of irradiated donor cells in prior human transplantation studies is difficult to determine because the cells were donor-derived and there was variable composition of the grafts utilized. 42 Our experiments focus on UCB transplantation, a setting where limiting numbers of cells are a frequent limitation and donor-derived T cells are not an option. Our results indicate an enhancement of engraftment, indicating that clinical trials of UCB transplantation with irradiated third-party allogeneic cells as an adjuvant are warranted.
